Cryptic Microheteroresistance Explains Mycobacterium tuberculosis Phenotypic Resistance

被引:30
作者
Metcalfe, John Z. [1 ]
Streicher, Elizabeth [2 ,3 ]
Theron, Grant [2 ,3 ]
Colman, Rebecca E. [4 ]
Allender, Christopher [5 ]
Lemmer, Darrin [5 ]
Warren, Rob [2 ,3 ]
Engelthaler, David M. [5 ]
机构
[1] Univ Calif San Francisco, San Francisco Gen Hosp, Div Pulm & Crit Care Med, 1001 Potrero Ave,Rm 5K1, San Francisco, CA 94110 USA
[2] Stellenbosch Univ, Fac Med & Hlth Sci, DST NRF Ctr Excellence Biomed TB Res, Tygerberg, South Africa
[3] Stellenbosch Univ, Fac Med & Hlth Sci, SAMRC Ctr TB Res, Div Mol Biol & Human Genet, Tygerberg, South Africa
[4] Univ Calif San Diego, Div Pulm Crit Care & Sleep Med, San Diego, CA 92103 USA
[5] Translat Genom Res Inst, Flagstaff, AZ USA
基金
新加坡国家研究基金会; 英国医学研究理事会;
关键词
next-generation sequencing; Sanger sequencing; drug-resistant tuberculosis; diagnostics; DRUG-RESISTANCE; FLUOROQUINOLONE RESISTANCE; STREPTOCOCCUS-PNEUMONIAE; HETERO-RESISTANCE; GENOMIC ANALYSIS; SOUTH-AFRICA; HETERORESISTANCE; SUSCEPTIBILITY; MUTATIONS; DIAGNOSIS;
D O I
10.1164/rccm.201703-0556OC
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Rationale: Minority drug-resistant Mycobacterium tuberculosis subpopulations can be associated with phenotypic resistance but are poorly detected by Sanger sequencing or commercial molecular diagnostic assays. Objectives: To determine the role of targeted next-generation sequencing in resolving these minor variant subpopulations. Methods: We used single molecule overlapping reads (SMOR), a targeted next-generation sequencing approach that dramatically reduces sequencing error, to analyze primary cultured isolates phenotypically resistant to rifampin, fluoroquinolones, or aminoglycosides, but for which Sanger sequencing found no resistance-associated variants (RAVs) within respective resistance-determining regions (study group). Isolates also underwent single-colony selection on antibiotic-containing agar, blinded to sequencing results. As a positive control, isolates with multiple colocalizing chromatogram peaks were also analyzed (control group). Measurements and Main Results: Among 61 primary culture isolates (25 study group and 36 control group), SMOR described 66 (49%) and 45 (33%) of 135 total heteroresistant RAVs at frequencies less than 5% and less than 1% of the total mycobacterial population, respectively. In the study group, SMOR detected minor resistant variant subpopulations in 80% (n = 20/25) of isolates with no Sanger-identified RAVs (median subpopulation size, 1.0%; interquartile range, 0.2-3.9%). Single-colony selection on drug-containing media corroborated SMOR results for 90% (n = 18/20) of RAV-containing specimens, and the absence of RAVs in 60% (n = 3/5) of isolates. Overall, Sanger sequencing was concordant with SMOR for 77% (n = 53/69) of macroheteroresistant (5-95% total population), but only 5% of microheteroresistant (< 5%) subpopulations (n = 3/66) across both groups. Conclusions: Cryptic minor variant mycobacterial subpopulations exist below the resolving capability of current drug susceptibility testing methodologies, and may explain an important proportion of false-negative resistance determinations.
引用
收藏
页码:1191 / 1201
页数:11
相关论文
共 50 条
  • [1] GWAS for quantitative resistance phenotypes in Mycobacterium tuberculosis reveals resistance genes and regulatory regions
    Farhat, Maha R.
    Freschi, Luca
    Calderon, Roger
    Ioerger, Thomas
    Snyder, Matthew
    Meehan, Conor J.
    de Jong, Bouke
    Rigouts, Leen
    Sloutsky, Alex
    Kaur, Devinder
    Sunyaev, Shamil
    van Soolingen, Dick
    Shendure, Jay
    Sacchettini, Jim
    Murray, Megan
    NATURE COMMUNICATIONS, 2019, 10 (1)
  • [2] Tools to Alleviate the Drug Resistance in Mycobacterium tuberculosis
    Rabaan, Ali A.
    Al Mutair, Abbas
    Albayat, Hawra
    Alotaibi, Jawaher
    Sulaiman, Tarek
    Aljeldah, Mohammed
    Al Shammari, Basim R.
    Alfaraj, Amal H.
    Al Fares, Mona A.
    Alwarthan, Sara
    Binjomah, Abdulwahab Z.
    Alzahrani, Mohammed S.
    Alhani, Hatem M.
    Almogbel, Mohammed S.
    Abuzaid, Abdulmonem A.
    Alqurainees, Ghaya
    Al Ibrahim, Fatimah
    Alhaddad, Ali H.
    Alfaresi, Mubarak
    Al-baghli, Nadira
    Alhumaid, Saad
    MOLECULES, 2022, 27 (20):
  • [3] Mutations in dnaA and a cryptic interaction site increase drug resistance in Mycobacterium tuberculosis
    Hicks, Nathan D.
    Giffen, Samantha R.
    Culviner, Peter H.
    Chao, Michael C.
    Dulberger, Charles L.
    Liu, Qingyun
    Stanley, Sydney
    Brown, Jessica
    Sixsmith, Jaimie
    Wolf, Ian D.
    Fortune, Sarah M.
    PLOS PATHOGENS, 2020, 16 (11)
  • [4] Ofloxacin Resistance in Mycobacterium tuberculosis Is Associated with Efflux Pump Activity Independent of Resistance Pattern and Genotype
    Sun, Zhaogang
    Xu, Yuhui
    Sun, Yong
    Liu, Yi
    Zhang, Xuxia
    Huang, Hairong
    Li, Chuanyou
    MICROBIAL DRUG RESISTANCE, 2014, 20 (06) : 525 - 532
  • [5] Phenotypic and genotypic characterization of Mycobacterium tuberculosis pyrazinamide resistance-India, 2018-2020
    Tamilzhalagan, Sembulingam
    Justin, Evanslin Santus
    Selvaraj, Ashok
    Venkateswaran, Karthick
    Sivakumar, Arun Kumar
    Chittibabu, Suganthi
    Mclaughlin, Heather P.
    Moonan, Patrick K.
    Smith, Jonathan P.
    Suba, Sakthi
    Narayanan, Mukesh Kumar Sathya
    Ho, Christine S.
    Kumar, Nishant
    Tripathy, Srikanth P.
    Shanmugam, Siva K.
    Hall-Eidson, Patricia J.
    Ranganathan, Uma Devi
    FRONTIERS IN MICROBIOLOGY, 2025, 15
  • [6] DETECTION OF RESISTANCE TO ANTI-TUBERCULOSIS DRUGS IN THE CLINICAL ISOLATES OF MYCOBACTERIUM TUBERCULOSIS FROM SLOVAKIA THROUGH COMPARISON BETWEEN PHENOTYPIC AND GENETIC METHODS AND EVALUATION OF RESISTANCE LEVELS WITH CLINICAL PARAMETERS
    Mokry, J.
    Porvaznik, I
    Kusnir, P.
    Dohal, M.
    Solovic, I
    JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2019, 70 (01): : 105 - 114
  • [7] Pyrazinamide resistance in Mycobacterium tuberculosis arises after rifampicin and fluoroquinolone resistance
    Alame-Emane, A. K.
    Xu, P.
    Pierre-Audigier, C.
    Cadet-Daniel, V.
    Shen, X.
    Sraouia, M.
    Siawaya, J. F. Djoba
    Takiff, H.
    Gao, Q.
    Gicquel, B.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2015, 19 (06) : 679 - 684
  • [8] Genomic Analysis of the Evolution of Fluoroquinolone Resistance in Mycobacterium tuberculosis Prior to Tuberculosis Diagnosis
    Zhang, Danfeng
    Gomez, James E.
    Chien, Jung-Yien
    Haseley, Nathan
    Desjardins, Christopher A.
    Earl, Ashlee M.
    Hsueh, Po-Ren
    Hung, Deborah T.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (11) : 6600 - 6608
  • [9] Actionable mechanisms of drug tolerance and resistance in Mycobacterium tuberculosis
    Datta, Dipanwita
    Jamwal, Shaina
    Jyoti, Nishant
    Patnaik, Srinivas
    Kumar, Dhiraj
    FEBS JOURNAL, 2024, 291 (20) : 4433 - 4452
  • [10] Genotypic and phenotypic characterization of Mycobacterium tuberculosis resistance against fluoroquinolones in the northeast of Iran
    Sayadi, Mahdieh
    Zare, Hosna
    Jamedar, Saeed Amel
    Hashemy, Seyed Isaac
    Meshkat, Zahra
    Soleimanpour, Saman
    Hoffner, Sven
    Ghazvini, Kiarash
    BMC INFECTIOUS DISEASES, 2020, 20 (01)